Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Berlin, Germany.
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
Cell Mol Gastroenterol Hepatol. 2023;15(6):1277-1292. doi: 10.1016/j.jcmgh.2023.02.010. Epub 2023 Feb 23.
Nonalcoholic fatty liver disease (NAFLD) is a fast growing, chronic liver disease affecting ∼25% of the global population. Nonalcoholic fatty liver disease severity ranges from the less severe simple hepatic steatosis to the more advanced nonalcoholic steatohepatitis (NASH). The presence of NASH predisposes individuals to liver fibrosis, which can further progress to cirrhosis and hepatocellular carcinoma. This makes hepatic fibrosis an important indicator of clinical outcomes in patients with NASH. Hepatic stellate cell activation dictates fibrosis development during NASH. Here, we discuss recent advances in the analysis of the profibrogenic pathways and mediators of hepatic stellate cell activation and inactivation, which ultimately determine the course of disease in nonalcoholic fatty liver disease/NASH.
非酒精性脂肪性肝病（NAFLD）是一种快速发展的慢性肝脏疾病，影响全球约 25%的人口。非酒精性脂肪性肝病的严重程度从较轻的单纯性肝脂肪变性到较严重的非酒精性脂肪性肝炎（NASH）不等。NASH 的存在使个体易患肝纤维化，肝纤维化可进一步进展为肝硬化和肝细胞癌。这使得肝纤维化成为 NASH 患者临床结局的一个重要指标。肝星状细胞激活决定了 NASH 期间纤维化的发展。在这里，我们讨论了分析肝星状细胞激活和失活的致纤维化途径和介质的最新进展，这些进展最终决定了非酒精性脂肪性肝病/ NASH 的疾病进程。
